Patents by Inventor Shubh Sharma
Shubh Sharma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220226425Abstract: The disclosure is related to a method of treating a disorder, such as obesity or a condition associated with obesity, such as hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist.Type: ApplicationFiled: April 4, 2022Publication date: July 21, 2022Inventors: Leonardus H.T. Van Der Ploeg, Barton T. Henderson, Shubh Sharma
-
Publication number: 20220160818Abstract: The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.Type: ApplicationFiled: August 13, 2021Publication date: May 26, 2022Inventors: Shubh Sharma, Leonardus H.T. Van Der Ploeg, Bart T. Henderson
-
Publication number: 20220118122Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radiotherapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.Type: ApplicationFiled: December 28, 2021Publication date: April 21, 2022Inventors: Kaushik DAVE, Shubh SHARMA
-
Patent number: 11241512Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.Type: GrantFiled: June 28, 2019Date of Patent: February 8, 2022Assignee: Actinium Pharmaceuticals, Inc.Inventors: Kaushik Dave, Shubh Sharma
-
Patent number: 11129869Abstract: The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.Type: GrantFiled: March 14, 2014Date of Patent: September 28, 2021Assignee: RHYTHM PHARMACEUTICALS, INC.Inventors: Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart Henderson
-
Publication number: 20210040155Abstract: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.Type: ApplicationFiled: October 26, 2020Publication date: February 11, 2021Inventors: Shubh Sharma, Leonardus H.T. Van Der Ploeg, Bart Henderson
-
Patent number: 10858399Abstract: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.Type: GrantFiled: December 11, 2018Date of Patent: December 8, 2020Assignee: RHYTHM PHARMACEUTICALS, INC.Inventors: Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart Henderson
-
Publication number: 20190321498Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radio-therapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.Type: ApplicationFiled: June 28, 2019Publication date: October 24, 2019Applicant: Actinium Pharmaceuticals, Inc.Inventors: Kaushik DAVE, Shubh SHARMA
-
Patent number: 10420851Abstract: Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition. The stabilized radiolabeled murine antibody binding the CD45 antigen expressed on various forms of lymphomas is useful as a radiotherapeutic and diagnostic agent in the treatment of human malignancies of hematopoietic origin, including lymphomas.Type: GrantFiled: May 24, 2017Date of Patent: September 24, 2019Assignee: Actinium Pharmaceuticals, Inc.Inventors: Kaushik Dave, Shubh Sharma
-
Publication number: 20190092815Abstract: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.Type: ApplicationFiled: December 11, 2018Publication date: March 28, 2019Inventors: Shubh Sharma, Leonardus H.T. Van Der Ploeg, Bart Henderson
-
Patent number: 10196425Abstract: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.Type: GrantFiled: March 14, 2014Date of Patent: February 5, 2019Assignee: RHYTHM PHARMACEUTICALS, INC.Inventors: Shubh Sharma, Leonardus H. T. Van Der Ploeg, Bart Henderson
-
Publication number: 20180215790Abstract: The disclosure is related to a method of treating a disorder, such as obesity or a condition associated with obesity, such as hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist.Type: ApplicationFiled: September 29, 2016Publication date: August 2, 2018Applicant: Rhythm Pharmaceuticals, Inc.Inventors: Leonardus H.T. Van Der Ploeg, Bart Henderson, Shubh Sharma
-
Publication number: 20160022764Abstract: The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.Type: ApplicationFiled: March 14, 2014Publication date: January 28, 2016Inventors: Shubh Sharma, Leonardus H.T. Van Der Ploeg, Bart Henderson
-
Publication number: 20160017001Abstract: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.Type: ApplicationFiled: March 14, 2014Publication date: January 21, 2016Inventors: Shubh Sharma, Leonardus H.T. Van Der Ploeg, Bart Henderson
-
Publication number: 20080070921Abstract: There is provided compounds having the formula of structure I: wherein the groups —C(R8)(CH2)vCH(R9)(CH2)y-Q and —C(R8)(CH2)vCH(R9)(CH2)y-J are the same, and R1a, R1b, R2a, R2b, R8, R9, J, Q, W, X, L2, v and y have meanings given in the description. Thus use of such compounds in the treatment of a condition responsive to changes in melanocortin receptor function in a human or non-human mammal (e.g. male sexual dysfunction, female sexual dysfunction, an eating disorder, above optimal body weight, obesity, below-optimal body weight or cachexia) is also described.Type: ApplicationFiled: August 10, 2007Publication date: March 20, 2008Applicant: Palatin Technologies, Inc.Inventors: Kevin Burris, Yi-Qun Shi, Shubh Sharma, Yadi Bonuga, Papireddy Purma
-
Patent number: 7307063Abstract: Metallopeptides are provided for use in treatment of sexual dysfunction in mammals. The metallopeptides are agonists for at least one of melanocortin-3 or melanocortin-4 receptors. The metallopeptides are conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion. Also provided are metallopeptides that are antagonists for at least one of melanocortin-3 or melanocortin-4 receptors.Type: GrantFiled: August 13, 2003Date of Patent: December 11, 2007Assignee: Palatin Technologies, Inc.Inventors: Shubh Sharma, Annette Shadiack, Yi-Qun Shi, Wei Yang, Hui-Zhi Cai
-
Publication number: 20070265206Abstract: Cyclic constructs with an N-terminus and a C-terminus which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I: where R, R?, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of anti-hypertensive, cardiovascular, renal or endocrine effects are desired.Type: ApplicationFiled: March 30, 2007Publication date: November 15, 2007Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Shubh Sharma, Margarita Bastos, Wei Yang, Hui-Zhi Cai
-
Publication number: 20070260040Abstract: Ring-constrained amino acid surrogates of formula I: where R1, R2, R3, R4, R5, R6a, R6b, R7, and y are as defined in the specification, methods for synthesizing ring-constrained amino acid surrogates of formula I, methods of use of ring-constrained amino acid surrogates of formula I, including use in linear or cyclic compounds which include a plurality of amino acid residues and one or more ring-constrained amino acid surrogates of formula I and linear or cyclic compounds which include a plurality of amino acid residues and one or more ring-constrained amino acid surrogates of formula I.Type: ApplicationFiled: March 30, 2007Publication date: November 8, 2007Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Shubh Sharma, Margarita Bastos, Wei Yang, Hui-Zhi Cai
-
Publication number: 20070155670Abstract: Melanocortin receptor-specific pyrrolidine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.Type: ApplicationFiled: March 1, 2007Publication date: July 5, 2007Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Shubh Sharma, Yi-Qun Shi, Zhijun Wu, Ramesh Rajpurohit
-
Patent number: 7176279Abstract: A cyclic peptide with a C-terminus —OH group. Further provided are compositions and methods for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, by administration of a cyclic peptide including a C-terminus —OH group. Methods of administration include injection, oral, urethral, vaginal, nasal and mucosal administration.Type: GrantFiled: August 8, 2003Date of Patent: February 13, 2007Assignee: Palatin Technologies, Inc.Inventors: Shubh Sharma, Annette Shadiack, Ramesh Rajpurohit, Wei Yang